<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622671</url>
  </required_header>
  <id_info>
    <org_study_id>K/ZDS/007961</org_study_id>
    <nct_id>NCT03622671</nct_id>
  </id_info>
  <brief_title>Fibrin Clot Properties and Blood Loss Following Coronary Artery By-pass Grafting</brief_title>
  <official_title>Association of Fibrin Clot Properties With Blood Loss Following Coronary Artery By-pass Grafting - Does Surgical Technique of Left Internal Mammary Artery Harvesting Matter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jagiellonian University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jagiellonian University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 15% of operations in cardio-pulmonary by-pass are complicated by excessive
      postoperative blood loss, which negatively affects the outcomes. Recently, it has been
      demonstrated that fibrin clot susceptibility to lysis is a modulator of postoperative blood
      loss after cardiac surgery for aortic stenosis. Earlier, a preliminary study showed a
      negative association of postoperative blood loss after coronary artery by-pass grafting
      (CABG) with fibrin clot lysis time, reflecting susceptibility to fibrinolysis.

      In CABG, postoperative blood loss may depend on the operative technique with respect to left
      internal mammary artery (LIMA) harvesting. LIMA is taken down in virtually all CABG
      procedures, but harvesting technical details remain at surgeons discretion (skeletonization
      without opening the pleural cavity vs. pedicled graft with pleura wide open).

      The investigators decided to test the hypothesis that fibrin clot properties modulate the
      postoperative drainage following CABG strongly enough to attenuate the influence of surgical
      technique by randomizing the patients undergoing CABG with regard to LIMA harvesting
      technique.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 26, 2018</start_date>
  <completion_date type="Actual">February 10, 2020</completion_date>
  <primary_completion_date type="Actual">December 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial with parallel group design. Equal allocation.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>The patient will be blinded to LIMA harvesting technique. The laboratory technicians will be blinded to LIMA harvesting technique.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative chest-tube output after 12 hours</measure>
    <time_frame>12 hours from the end of operation</time_frame>
    <description>Drainage volume after 12 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative myocardial infarction</measure>
    <time_frame>48 hours after the procedure</time_frame>
    <description>Change in myocardial necrosis biomarkers (Troponin T, creatine kinase) during first 48 hours postoperatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Internal Mammary-Coronary Artery Anastomosis</condition>
  <condition>Coronary Artery Bypass</condition>
  <condition>Blood Loss, Postoperative</condition>
  <condition>Fibrinolysis</condition>
  <arm_group>
    <arm_group_label>Skeletonized LIMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients in this arm the left internal mammary artery will be skeletonized without opening of the left pleural cavity during CABG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pedicled LIMA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients in this arm the left internal mammary artery will be harvested as a pedicled graft with wide opening of left pleural cavity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skeletonized LIMA</intervention_name>
    <description>Standard CABG - no different form any other procedure of this type except LIMA will be skeletonized without opening the pleura</description>
    <arm_group_label>Skeletonized LIMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Pedicled LIMA</intervention_name>
    <description>Standard CABG - no different form any other procedure of this type except LIMA will be taken down as a pedicled graft with opening the pleura</description>
    <arm_group_label>Pedicled LIMA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Angiographically confirmed coronary artery disease

          -  Heart Team qualification for first time elective coronary artery by-pass grafting

          -  No significant valvular disease or congenital heart disease

          -  Normal sinus rhythm on ECG

          -  Continued aspirin in perioperative period

        Exclusion Criteria:

          -  Need for any concomitant cardiac procedure

          -  St. p. percutaneous coronary intervention within preceding 3 months

          -  Any previous cardiac surgery

          -  Known bleeding diathesis

          -  Acute cardiovascular incident within preceding 3 months

          -  Heart failure with left ventricular ejection fraction &lt;30%

          -  Any autoimmune disease

          -  Any acute infection

          -  Known neoplasm

          -  Any thyroid disease

          -  Treatment with any thienopyridine, oral anticoagulant, heparin or any non-steroid
             anti-inflammatory agent other than aspirin

          -  Mental disorder

          -  Severe comorbidities (liver failure, renal failure on hemodialysis)

          -  Lacking consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piotr Mazur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jagiellonian University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The John Paul II Hospital</name>
      <address>
        <city>Krak√≥w</city>
        <state>Malopolskie</state>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 3, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jagiellonian University</investigator_affiliation>
    <investigator_full_name>Piotr Mazur</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery By-pass Grafting</keyword>
  <keyword>CABG</keyword>
  <keyword>Fibrin</keyword>
  <keyword>Clot Lysis Time</keyword>
  <keyword>CLT</keyword>
  <keyword>Bleeding</keyword>
  <keyword>Drainage</keyword>
  <keyword>Rethoracotomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

